SELLAS Life Sciences (SLS) Shares Outstanding (Weighted Average) (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $172.5 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $172.5 million, up 119.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $172.5 million (up 119.84% YoY), and the FY2025 annual result was $109.1 million, up 78.18% from the prior year.
• Shares Outstanding (Weighted Average) advanced to $172.5 million in Q1 2026 per SLS's latest filing, from $22.4 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $172.5 million in Q1 2026 and troughed at $518000.0 in Q1 2022.
• A 5-year average of $44.8 million and a median of $28.3 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Weighted Average) soared 3585.01% in 2022, then slumped 63.46% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $5.1 million in 2022, then surged by 40.17% to $7.2 million in 2023, then surged by 749.33% to $61.2 million in 2024, then tumbled by 63.46% to $22.4 million in 2025, then jumped by 671.25% to $172.5 million in 2026.
• Business Quant data shows SLS's Shares Outstanding (Weighted Average) at $172.5 million in Q1 2026, $22.4 million in Q4 2025, and $98.3 million in Q3 2025.